Zasocitinib NCT07250802 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 3

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2033-01-24

Primary-completion proxy

Executive view

NCT07250802 evaluates Zasocitinib in Plaque psoriasis. The disclosed sponsor is Takeda Pharmaceutical Co., Ltd., the design is Interventional, and the geographic footprint is United States, Japan, China, Poland, Italy, Germany, Spain. The first listed primary endpoint is Part A: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater than or Equal to (>=) 2-Point Decrease From Baseline at Week 16, assessed over At Week 16.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07250802 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Plaque psoriasis landscape. Drug & Asset MCP drug_fetch was queried for Zasocitinib, while Company & Deal Intelligence MCP organization_fetch was queried for Takeda Pharmaceutical Co., Ltd..

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT07250802	Zasocitinib	Phase 3 / Recruiting	Takeda Pharmaceutical Co., Ltd.	United States, Japan, China, Poland, Italy, Germany, Spain	Part A: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear… At Week 16	2033-01-24
NCT07373847	Recaticimab	Phase 4 / Not yet recruiting	Xiangya Hospital Central South University	Geography not reported	PASI 100 response rate at week 16 in the group treated with vunakizumab combined with recaticimab versus vunakizumab co… From enrollment to the end of treatment at 16 weeks	2027-06-30
NCT07366268	Apremilast	Not Applicable / Not yet recruiting	Assiut University	Geography not reported	Change in Psoriasis thickness,erythema, and scaling (TES score) from baseline to Week 12 Baseline to week 12 and two months after to detect recurrence .	2027-05-01
NCT07362017	Ponesimod	Phase 3 / Recruiting	Vanda Pharmaceuticals, Inc.	United States	Safety and tolerability of ponesimod as measured by reporting of adverse events (AEs) Through study completion, approximately 1 year	2028-08-01
NCT07357831	Betamethasone Dipropionate/Calcipotriene	Phase 3 / Completed	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	China	Physician's Global Assessment (PGA) success rate on the body (trunk and/or limbs) after 8 weeks of treatment with MC2-0… Baseline and 8-week	2026-08-06

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT07250802 is a Phase 3, recruiting study with not reported planned participants. Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment.

The primary endpoint is “Part A: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater than or Equal to (>=) 2-Point Decrease From Baseline at Week 16” over “At Week 16.” The retrieved endpoint description is: The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA composite score ranges from 0 to 4 and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean greater than (\>) 0, less than (\ = 1.5, \ =2.5, \ =3.5. The percentage of participants achieving an sPGA of Clear (0) or Almost Clear (1) with a \>= 2-point decrease from baseline at Week 16 will be reported..

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Plaque psoriasis. These records do not establish direct evidence for NCT07250802 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Zasocitinib is indexed as Small molecule drug with TYK2 biology and a global stage of Phase 3. The asset profile lists Nimbus Therapeutics LLC as an originator or developer.

Takeda Pharmaceutical Co., Ltd. is indexed in an unreported country with the website http://www.takeda.com. Engages in the research, development, manufacturing and marketing of pharmaceutical products The record lists 244 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Zasocitinib is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT07250802
Protocol source: https://clinicaltrials.gov/study/NCT07250802
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Zasocitinib in Plaque psoriasis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Part A: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1) With a Greater than or Equal to (>=) 2-Point Decrease From Baseline at Week 16 and 2033-01-24 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP